Siemens Healthineers Ag · XETR:SHL
Siemens Healthineers — Merger or Acquisition (August 2019)
8 slides from Siemens Healthineers's merger presentation, Aug 8, 2019
Slide 1: Shaping the future of healthcare
Shaping the future of healthcare Dr. Jochen Schmitz, CFO | Dr. Michel Therin, Head of Advanced Therapies August 8, 2019 Analyst Call, August 8 Unrestricted © Siemens Healthineers AG, 2019 | Page 1
Slide 2: Notes and forward looking statements
Notes and forward looking statements This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, yo
Slide 3: Tapping into adjacent growth markets – We execute on our strategy
Tapping into adjacent growth markets – We execute on our strategy Mid-term and beyond Mid-term New growth 2017-19 Upgrading Reinforcing Strategic Drive profitable growth Tap into adjacent "Market leadership 2025" posture in core business growth markets Strategic • Significant next generation Precisi
Slide 4: Advanced Therapies is set to capture growth
Advanced Therapies is set to capture growth Advanced Therapies at a glance FY2018 Clinical fields Growth opportunities in complex cases3) Interventional Cardiology €1.5bn Revenue Radiology Coronary CTO4) Revascularization +3% 19.6% Adjusted profit margin Peripheral Revascularization +6% Recurring se
Slide 5: Corindus is forerunner in robotic-assisted vascular interventions
Corindus is forerunner in robotic-assisted vascular interventions Corindus Vascular Robotics, Inc. • Corindus is active in the development, manufacturing and selling of robotic-assisted precision vascular systems, cassettes and services • Headquartered in Waltham, Massachusetts with ~100 employees •
Slide 6: Combining Relevance in Procedural
Set to shape the market for robotic cardiovascular, peripheral and neurovascular procedures Procedural leadership • Disruptive innovation pipeline for cardiovascular, peripheral and neurovascular with potential to shape endovascular robotics market • Forerunner in endovascular robotics with signific
Slide 7: Corindus is a valuable adjacency to our strong portfolio
Corindus is a valuable adjacency to our strong portfolio Terms & Approvals Financing, leverage & business profile post-closing • Acquisition of 100% of fully diluted common shares • Financed via new acquisition financing term loan by outstanding of Corindus (NYSE: CVRS) for $4.28 per share: Siemens
Slide 8: Analyst Call, August 8 Unrestricted © Siemens Healthineers AG, 2019 | Page 8
Analyst Call, August 8 Unrestricted © Siemens Healthineers AG, 2019 | Page 8
Siemens Healthineers — Merger or Acquisition (August 2019) on 6ix